Chris LeMasters
2017
In 2017, Chris LeMasters earned a total compensation of $502.3K as Executive Vice President and Chief Business Officer at Mirati Therapeutics, a 32% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $109,600 |
|---|---|
| Option Awards | $47,677 |
| Salary | $342,550 |
| Other | $2,500 |
| Total | $502,327 |
LeMasters received $342.6K in salary, accounting for 68% of the total pay in 2017.
LeMasters also received $109.6K in non-equity incentive plan, $47.7K in option awards and $2.5K in other compensation.
Rankings
In 2017, Chris LeMasters' compensation ranked 11,850th out of 14,666 executives tracked by ExecPay. In other words, LeMasters earned more than 19.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,850 out of 14,666 | 19th |
Division Manufacturing | 4,664 out of 5,772 | 19th |
Major group Chemicals And Allied Products | 1,701 out of 2,075 | 18th |
Industry group Drugs | 1,411 out of 1,731 | 19th |
Industry Pharmaceutical Preparations | 1,103 out of 1,333 | 17th |
Source: SEC filing on April 19, 2019.
LeMasters' colleagues
We found four more compensation records of executives who worked with Chris LeMasters at Mirati Therapeutics in 2017.
2017
Charles Baum
Mirati Therapeutics
Chief Executive Officer
2017
Isan Chen
Mirati Therapeutics
Executive Vice President and Chief Medical and Development Officer
2017
James Christensen
Mirati Therapeutics
Chief Scientific Officer
2017
Jamie Donadio
Mirati Therapeutics